Ling Wang
Sichuan University
59 Papers
240 Citations
Ling Wang is an academic researcher from Sichuan University. The author has contributed to research in topics: Pharmacokinetics & Chemistry. The author has an hindex of 12, co-authored 58 publications. Previous affiliations of Ling Wang include Rutgers University & The Chinese University of Hong Kong.
Chat about Author
Papers
Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles
TL;DR: It is demonstrated that PCs from clinical sources greatly influenced the active targeting capacities of transferrin-modified NPs (Tf-NPs) and the use of corona-enabled active targeting for precision nanomedicine is proposed.
60
Simultaneous quantification of active components in the herbs and products of Si-Wu-Tang by high performance liquid chromatography-mass spectrometry.
Zhijun Wang,Siukwan Wo,Ling Wang,Ling Wang,Clara Bik-San Lau,Vincent H.L. Lee,Moses S. S. Chow,Moses S. S. Chow,Zhong Zuo +8 more
TL;DR: A high performance liquid chromatography-mass spectrometric method employing both positive and negative electrospray ionization was developed for the simultaneous determination of the nine identified compounds in the raw herbs and products of Si-Wu-Tang.
57
Blocking of JB6 cell transformation by tanshinone IIA: epigenetic reactivation of Nrf2 antioxidative stress pathway
Ling Wang,Ling Wang,Chengyue Zhang,Yue Guo,Zheng-Yuan Su,Yuqing Yang,Limin Shu,Ah-Ng Tony Kong +7 more
TL;DR: Results show that TIIA activates the Nrf2 signaling pathway and induces epigenetic demethylation of the CpGs of NRF2.
55
Quantitative determination of rosuvastatin in human plasma by ion pair liquid-liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry.
TL;DR: The assay was successfully applied to the analysis of rosuvastatin in human plasma samples derived from clinical pre-trials and indicated that the lower limit of quantification (LLOQ) was 0.1 ng mL(-1) and the assay exhibited a linear range of 0.8% at all tested concentration levels.
54
Poly(ethylene glycol)-block-poly(ε-caprolactone)– and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery
TL;DR: Modification of liposomes with PEG2000-b-PCL2000 can simultaneously improve drug accumulation at the target tumor site and tumor cells, showing great promise for utilization as a PEG modification tool in the fabrication of stealth nanoparticles for cancer chemotherapy.